
A new oral therapy, TP-05, could transform Lyme disease prevention by targeting ticks before transmission, offering a flexible, on-demand option beyond traditional behavioral strategies in high-risk populations.
Roxana Francisco, MD, PhD, senior director, clinical development, Tarsus Pharmaceuticals
Roxana Francisco, MD, PhD, is a physician–scientist and clinical development leader with over a decade of experience advancing treatments for infectious and inflammatory diseases. At Tarsus Pharmaceuticals, Francisco focuses on developing innovative therapies and raising awareness of conditions like Lyme disease, with an emphasis on prevention, early detection, and patient care.
Francisco has held senior roles at organizations including Moderna, BioNTech, and the National Institutes of Health, contributing to global vaccine and infectious disease research programs.

A new oral therapy, TP-05, could transform Lyme disease prevention by targeting ticks before transmission, offering a flexible, on-demand option beyond traditional behavioral strategies in high-risk populations.